# US 2019/0168943 A1 · Packaging system for oxygen-sensitive drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0168943 A1
- Document ID: US20190168943A1
- Status: Published application
- Kind: A1
- Application number: 16/269,434
- Filed: 2019-02-06
- Published: 2019-06-06
- Earliest claimed: 2013-03-14
- Assignees: Fresenius Kabi Deutschland GmbH
- Applicants: Fresenius Kabi Deutschland GmbH
- Inventors: Thomas DEVOUASSOUX; Eric FORAT; James Kenneth PROCTOR
- Web page: https://patentgrep.com/patent/US20190168943A1

## CPC

- B65D 81/266: {for absorbing gases, e.g. oxygen absorbers or desiccants (B65D51/244, B65D51/30 take precedence)}
- A61B 50/30: Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments (for wound clamps A61B17/10; for ligaturing clips A61B17/122; packages or dispensers for surgical gloves or finger-stalls A61B42/40)
- A61B 50/3001: {for sharps}
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61M 5/002: {Packages specially adapted therefor, e.g. packages for syringes or needles or kits for diabetics}
- B65D 65/40: Applications of laminates for particular packaging purposes {(B65D1/0215, B65D1/28, B65D3/22, B65D5/0281, B65D5/563, B65D9/30, B65D29/02, B65D31/02, B65D75/26, B65D77/2024, B65D81/1275, B65D81/3811, B65D81/3823, B65D81/3834, B65D81/3846, B65D81/3858, B65D81/3874, B65D81/3886, B65D81/3897 take precedence; laminates per se or laminated packages characterised by the composition or)}
- B65D 75/36: one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages {, the recess or recesses being preformed (B65D73/0057, B65D73/0092 take precedence)}
- B65D 81/268: {the absorber being enclosed in a small pack, e.g. bag, included in the package}
- A61B 2050/3005: {containing a preservative liquid, e.g. an antiseptic liquid}
- B65D: CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Described herein are pharmaceutical packaging systems which prevent oxidative degradation of oxygen-sensitive drugs, such systems including a primary packaging container with an oxygen permeable component, a secondary packaging with very low permeability to oxygen and an oxygen absorber.

## Claims

### Claim 1

A pharmaceutical product comprising:
(i) a container filled under inert conditions with an injectable oxygen-sensitive drug, wherein the container has an oxygen permeable component,
(ii) a hermetically sealed oxygen barrier blister packaging which houses the container, wherein the blister packaging comprises a multilayer bottom web and a multilayer top web lid each comprised of an oxygen barrier material; and
(iii) an oxygen absorber inside the blister packaging, wherein the oxygen absorber reduces the oxygen level present from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the container, and the oxygen levels in the blister packaging and in the container remain at about zero percent for at least one year after the initial reduction in oxygen levels.

### Claim 2 (depends on 1)

The pharmaceutical product of claim 1, wherein the oxygen barrier material is selected from the group consisting of high density polyethylene (HDPE), low density polyethlyene (LDPE), ethylene/vinyl alcohol copolymer (EVOH), polyvinyl alcohol (PVOH), polyvinyl chloride (PVC), polyvinylidene chloride (PVDC), polychlorotrifluoroethylene (PCTFE), vinylidene chloride/methyl acrylate copolymer, polyester, polypropylene (PP), polyethylene terephthalate (PET), amorphous PET, glycol modified PET (PET-G), polyethylene naphthalate (PEN), ethylene acrylic acid copolymer (EAA), polyamide (PA), metalized film, aluminum foil, oxide coated films and combinations thereof.

### Claim 3 (depends on 2)

The pharmaceutical product of claim 2, wherein the oxygen barrier material is selected from the group consisting of EVOH, PVOH, PVC, PVDC, PCTFE, vinylidene chloride/methyl acrylate copolymer, polyamide, polyester, a metalized film, oxide coated films, and combinations thereof.

### Claim 4 (depends on 2)

The pharmaceutical product of claim 2, wherein the oxygen barrier material is is present in the form of a multilayer film.

### Claim 5 (depends on 4)

The pharmaceutical product of claim 4, wherein the multilayer film comprises PVC/EVOH, PET/EVOH, PET/EVOH/PE, PET/EVOH/PET, PE/EVOH/PE, PVC/PCTFE/EVOH, Paper/Aluminum(Alu)/PE, PET/Alu/PE, Paper/PE/foil/PE, Paper/PET/Alu, Clay-coated paper/PE/foil/LDPE, or Paper/LDPE/foil/EEA.

### Claim 6 (depends on 1)

The pharmaceutical product of claim 1, wherein the multilayer bottom web comprises polyethylene terephthalate (PET) and ethylene/vinyl alcohol copolymer (EVOH).

### Claim 7 (depends on 1)

The pharmaceutical product of claim 1, wherein the multilayer top web lid comprises polyethylene terephthalate (PET), aluminum foil, and paper.

### Claim 8 (depends on 1)

The pharmaceutical product of claim 1, wherein the container is a syringe, cartridge, or vial.

### Claim 9 (depends on 1)

The pharmaceutical product of claim 1, wherein the blister packaging is an aluminum-based cold formed blister, or a molded blister.

### Claim 10 (depends on 1)

The pharmaceutical product of claim 1, wherein the oxygen absorber is a canister.

### Claim 11 (depends on 1)

The pharmaceutical product of claim 1, wherein the oxygen absorber has a capacity to absorb about 30 cc oxygen at 1 atm.

### Claim 12 (depends on 1)

The pharmaceutical product of claim 1, wherein the oxygen absorber is iron-based.

### Claim 13 (depends on 1)

The pharmaceutical product of claim 1, wherein the oxygen absorber reduces the oxygen level in the blister packaging from the time of packaging assembly to about zero percent at about one day.

### Claim 14 (depends on 1)

The pharmaceutical product of claim 1, wherein the oxygen absorber reduces the oxygen level in the container from the time of packaging assembly to about zero percent at about one month.

### Claim 15 (depends on 1)

The pharmaceutical product of claim 1, wherein the oxygen level remains at about zero percent in the container and the blister packaging for at least three years.

### Claim 16 (depends on 1)

The pharmaceutical product of claim 1, wherein the blister packaging is a thermoformed blister.

### Claim 17 (depends on 1)

The pharmaceutical product of claim 1, wherein the oxygen absorber is selected from reduced iron compounds, catechol, ascorbic acid and analogs thereof, metal ligands, unsaturated hydrocarbons and polyamides.

### Claim 18 (depends on 1)

The pharmaceutical product of claim 1, wherein the oxygen absorber is a sachet, pouch, canister, capsule, label, sticker, strip, patch, cartridge or container.

### Claim 19 (depends on 1)

The pharmaceutical product of claim 1, wherein the drug comprises an amine, a sulfide, an allylic alcohol, a phenol or another chemical group that can have reactivity with oxygen.

### Claim 20 (depends on 1)

The pharmaceutical product of claim 1, wherein the drug is selected from morphine, hydromorphone, promethazine, dopamine, epinephrine, norepinephrine, esterified estrogen, ephedrine, pseudoephedrine, acetaminophen, ibuprofen, danofloxacin, erythromycin, penicillin, cyclosporine, methyldopate, cetirizine, diltiazem, verapamil, mexiletine, chlorothiazide, carbamazepine, selegiline, oxybutynin, vitamin A, vitamin B, vitamin C, L cysteine and L-tryptophan.

### Claim 21

A pharmaceutical product comprising:
(i) a container filled under inert conditions with morphine, wherein the container has an oxygen permeable component,
(ii) a hermetically sealed oxygen barrier blister packaging which houses the container, wherein the blister packaging comprises a multilayer bottom web and a multilayer top web lid each comprised of an oxygen barrier material; and
(iii) an oxygen absorber inside the blister packaging, wherein the oxygen absorber reduces the oxygen level present from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the container, and the oxygen levels in the blister packaging and in the container remain at about zero percent for at least one year after the initial reduction in oxygen levels.

### Claim 22

A pharmaceutical product comprising:
(i) a container filled under inert conditions with hydromorphone, wherein the container has an oxygen permeable component,
(ii) a hermetically sealed oxygen barrier blister packaging which houses the container, wherein the blister packaging comprises a multilayer bottom web and a multilayer top web lid each comprised of an oxygen barrier material; and
(iii) an oxygen absorber inside the blister packaging, wherein the oxygen absorber reduces the oxygen level present from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the container, and the oxygen levels in the blister packaging and in the container remain at about zero percent for at least one year after the initial reduction in oxygen levels.
